Programmed death-ligand 1 (PD-L1) has historically been recognized primarily for its capacity to enable cancer cells to evade immune destruction by dampening the activity of cytotoxic T cells. However, recent investigations have suggested that PD-L1’s functions may not be confined to immune evasion. In this paradigm-shifting study, Prof. Lee and his team intricately examined patient-derived non-small cell lung cancer (NSCLC) datasets employing comprehensive transcriptomic analyses coupled with robust molecular and functional assays, thereby unveiling PD-L1 as a pivotal modulator of autophagy and metastasis-associated signaling axes within tumor cells.

The researchers harnessed CRISPR-Cas9 genome editing technology to generate PD-L1 knockout lung cancer cell models, revealing profound alterations in cellular behaviors. The ablation of PD-L1 was shown to diminish cell proliferation rates significantly, impair migratory capabilities, and hamper the cells’ colony-forming efficiency in vitro. These phenotypic changes underline the indispensable role of PD-L1 in sustaining tumor cell viability and motility, facets that are quintessential for metastatic dissemination. The study expanded these observations in vivo through xenograft mouse models, where PD-L1 depletion led to a marked attenuation of both tumor growth and metastatic spread.

Mechanistically, the study elucidated that PD-L1 orchestrates autophagy—a conserved catabolic process critical for cellular homeostasis and survival under stress—by modulating the signaling cascade involving Toll-like receptor (TLR) stimulation. Upon TLR activation, PD-L1 was found to engage directly with the adaptor protein TRAF6 and the autophagy initiator BECN1 (Beclin-1), forming a signaling axis that accelerates autophagy induction within lung cancer cells. This pathway not only supports cellular survival under adverse microenvironmental conditions but also appears to promote metastatic competency by facilitating cellular adaptation and motility.

The discovery of PD-L1’s direct regulatory role in autophagy through the TRAF6–BECN1 signaling axis introduces a novel conceptual framework in cancer biology, situating PD-L1 as an integral component bridging immune signaling and intracellular metabolic pathways. This dual functionality suggests that inhibiting PD-L1 could yield a dual therapeutic benefit—reactivating anti-tumor immune responses while concurrently disarming cancer cell-intrinsic survival mechanisms. Such integrated targeting strategies bear potential for enhancing the efficacy of current immunotherapies and overcoming resistance mechanisms frequently observed in lung cancer treatment.

Notably, this investigation employed an array of proteomic interaction experiments corroborating the physical association between PD-L1 and key autophagy regulators, complemented by transcriptomic alterations observed in patient tumor specimens. By demonstrating that PD-L1’s oncogenic effects extend beyond immune checkpoint pathways, Prof. Lee’s work underscores the complexity of molecular signaling networks driving lung cancer progression and emphasizes the importance of considering tumor-intrinsic factors during drug development.

Furthermore, the study sheds light on the influence of TLR-mediated signaling in tumor biology, which traditionally has been associated with innate immune responses. The cross-talk elucidated between TLR activation and PD-L1-driven autophagy provides new insights into how tumor cells exploit immune-related pathways to enhance survival and invasive potential. This crosstalk offers promising targets for therapeutic intervention, aiming to disrupt the symbiotic relationship between immune evasion and cell-autonomous oncogenic pathways.

The translational implications of this research are substantial. By delineating a novel PD-L1-centered signaling mechanism, the findings advocate for the development of sophisticated multi-omics platforms to further dissect the molecular heterogeneity of lung cancer. Prof. Lee’s team plans to expand this research trajectory, integrating genomic, transcriptomic, and proteomic data to refine precision medicine approaches that can stratify patients based on tumor-intrinsic PD-L1 activity and tailor therapies accordingly.

This advance comes at a crucial moment in oncology research, as lung cancer remains the leading cause of cancer-related mortality worldwide, with NSCLC constituting the majority of cases. Therapeutic resistance and disease recurrence continue to pose formidable challenges; thus, interventions informed by a detailed understanding of tumor biology, like those elucidated in this study, are urgently needed to improve long-term clinical outcomes.

The research received support from the Ministry of Science and ICT and the National Research Foundation of Korea through the MRC and Mid-career Researcher Programs, highlighting the vital role of governmental funding in enabling high-impact cancer research. The study’s publication in the prestigious journal Experimental Hematology & Oncology further attests to the significance and quality of this work, with an impressive Impact Factor of 13.5 placing it in the top 5.6% in the Journal Citation Reports.

Prof. Ki-Young Lee and his team’s seminal work redefines our understanding of PD-L1’s role in lung cancer, providing a compelling narrative that intertwines tumor immunology and cell biology. By unveiling PD-L1’s function as a driver of autophagy and metastasis through the TRAF6–BECN1 axis post-TLR stimulation, this study not only challenges existing paradigms but also ignites new momentum toward developing innovative cancer therapies that are finely tuned to disrupt tumor-intrinsic survival and dissemination pathways.

Subject of Research: Lung cancer progression mechanisms; PD-L1 intrinsic tumor functions; autophagy regulation; TLR signaling in cancer cells.

Article Title: Tumor-intrinsic PD-L1 drives lung cancer progression in response to TLR stimulation by promoting autophagy through the TRAF6–BECN1 signaling axis

News Publication Date: February 16, 2026

Web References: http://dx.doi.org/10.1186/s40164-026-00761-9

Keywords: PD-L1, lung cancer, non-small cell lung cancer (NSCLC), autophagy, tumor progression, TRAF6, BECN1, Toll-like receptor (TLR), CRISPR-Cas9, metastasis, immune checkpoint, cancer signaling

To unravel the molecular underpinnings driving acquired resistance to platinum agents, the researchers established robust cisplatin-resistant TNBC cell lines by subjecting sensitive parental cultures (231-pa and 468-pa) to prolonged treatment with escalating cisplatin doses. These resistant derivatives, designated 231-cisR and 468-cisR, exhibited dramatically diminished sensitivity to cisplatin, enabling a comparative transcriptomic and proteomic analysis that revealed the upregulation of a circular RNA (circRNA) known as circSCAP. This circRNA was preferentially enriched in resistant cells in vitro and in platinum-refractory tumor specimens from patients, implicating it as a key player in the resistance phenotype.

What sets this discovery apart is the revelation that circSCAP is not merely a non-coding RNA but harbors intrinsic protein-coding potential. Advanced bioinformatics and experimental assays demonstrated that circSCAP contains a functional internal ribosome entry site (IRES), facilitating cap-independent translation, along with a conserved open reading frame (ORF) that encodes a novel 129-amino-acid peptide, termed SCAP-129aa. This circRNA-encoded micropeptide was validated by immunoblotting and immunohistochemistry in resistant TNBC cells and clinical tissue samples, where its expression paralleled that of the circRNA. The confirmation of circSCAP’s translation challenges the conventional dogma that circRNAs serve solely regulatory or sponging roles, underscoring an emerging landscape of circRNA-derived functional peptides in cancer biology.

Functional dissection of SCAP-129aa’s role established it as a direct mediator of platinum resistance. Knockdown of circSCAP via shRNAs specific to its back-splice junction curtailed SCAP-129aa production, subsequently restoring cisplatin sensitivity in resistant cells. These cells exhibited enhanced apoptosis and DNA damage responses upon cisplatin treatment, suggesting SCAP-129aa confers protective mechanisms against genotoxic stress. In stark contrast, enforced expression of wild-type circSCAP, capable of translation, induced resistance in previously sensitive cells, whereas a mutant lacking the critical ATG start codon failed to do so, consolidating the indispensability of the peptide product for resistance.

To elucidate the mechanistic basis of SCAP-129aa’s influence, the team employed co-immunoprecipitation coupled with mass spectrometry to identify interacting partners. They discovered a high-affinity binding between SCAP-129aa and PIK3R2 (p85β), a regulatory subunit of the phosphoinositide 3-kinase (PI3K) complex integral to the PI3K/AKT signaling axis. Intriguingly, this interaction was mapped to the SH2C domain of PIK3R2, a region pivotal for its ubiquitination and subsequent proteasomal degradation. Binding of SCAP-129aa to this domain inhibited PIK3R2 ubiquitination, stabilizing the protein and amplifying PI3K signaling, which is well-known to promote cell survival, proliferation, and DNA repair. Through this stabilization, SCAP-129aa effectively enables TNBC cells to resist cisplatin-induced cytotoxicity by activating pro-survival pathways and enhancing DNA damage repair capacity.

Further in vivo studies using orthotopic xenograft models of platinum-resistant TNBC in immunodeficient NOD/SCID mice reinforced these findings. Silencing circSCAP expression in resistant tumors led to pronounced re-sensitization to cisplatin, significantly reducing tumor volume and growth rate. Notably, the combination of cisplatin with a PIK3R2-specific inhibitor further improved therapeutic outcomes in resistant tumors but showed no additional effect in parental sensitive tumors, highlighting the selective vulnerability conferred by the SCAP-129aa–PIK3R2 axis in resistant settings.

The clinical significance of SCAP-129aa was corroborated through immunohistochemical analysis of 73 TNBC patient tumor samples. High SCAP-129aa expression correlated with substantially worse overall survival (hazard ratio = 5.912, log-rank P = 0.0004), indicating its potential as a prognostic biomarker. Elevated SCAP-129aa also associated with increased lymph node and distant metastases, more advanced AJCC staging, higher Ki67 proliferation indices, and a pronounced prevalence of platinum resistance—all markers of aggressive disease behavior and poor clinical outcomes.

This pioneering study delivers compelling evidence that the circRNA-encoded peptide SCAP-129aa is a critical driver of platinum resistance in TNBC, acting through direct modulation of the PI3K/AKT pathway. These insights not only redefine our understanding of circRNA functionality but also spotlight SCAP-129aa and its interaction with PIK3R2 as promising therapeutic targets. Strategies aimed at disrupting this axis could potentially restore chemotherapy efficacy and improve prognosis in patients facing platinum-resistant TNBC.

“Platinum resistance remains a critical barrier in the effective treatment of triple-negative breast cancer,” remarked Qiang Liu, a senior author of the study. “Our identification of a circRNA-encoded protein mediating this resistance uncovers a previously unappreciated mechanism and highlights new molecular targets to overcome therapeutic failure.”

At the confluence of RNA biology and cancer therapeutics, this research from Sun Yat-sen University Sun Yat-sen Memorial Hospital exemplifies how translational investigations can unravel complex resistance networks in aggressive cancers. Their work lays the foundation for the development of novel inhibitors against SCAP-129aa or the stabilization machinery of PIK3R2, potentially transforming the treatment landscape for TNBC patients who currently have limited options beyond chemotherapy.

The findings underscore the necessity of integrating cutting-edge molecular techniques, including circRNA profiling, peptide identification, and proteomic analyses, to uncover clinically relevant pathways. In doing so, the study paves the way for personalized medicine approaches, where tumors with elevated circSCAP or SCAP-129aa expression could be stratified for specific targeted therapies, maximizing clinical response while minimizing toxicity.

Future research is warranted to explore the broader implications of circRNA-derived peptides in oncology and to develop effective pharmacologic agents disrupting the SCAP-129aa and PIK3R2 interaction. Such endeavors will be crucial steps toward overcoming drug resistance and improving survival outcomes for patients afflicted with triple-negative breast cancer.

Subject of Research: Platinum resistance mechanisms in triple-negative breast cancer mediated by circRNA-encoded peptides

Article Title: circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway

Web References:
http://dx.doi.org/10.1007/s11427-024-2946-1

Image Credits: ©Science China Press

Keywords: triple-negative breast cancer, platinum resistance, circSCAP, SCAP-129aa, circRNA, protein-coding circRNAs, PI3K/AKT pathway, PIK3R2, ubiquitination, cisplatin, drug resistance mechanism, targeted therapy

In a groundbreaking investigation, researchers undertook an unbiased, integrative analysis of the full RNA landscape—or RNAome—encompassing both coding and non-coding RNAs extracted from skeletal muscle biopsies of patients afflicted with colorectal or pancreatic cancer. The rectus abdominis muscle, favored for its accessibility and clinical relevance, served as the tissue of choice. High-throughput next-generation sequencing generated vast data sets enabling a holistic view of transcriptomic alterations in diseased muscle tissue. To delve deep into the biological heterogeneity, the team applied integrative non-negative matrix factorization (iNMF), a powerful unsupervised clustering algorithm designed to dissect complex multi-modal data into coherent subgroups without preconceived hypotheses.

The application of iNMF revealed the existence of two distinct molecular subtypes within the skeletal muscle of cancer patients. These subtypes exhibited significant divergence not only at the molecular level but also in clinical phenotype, with patients assigned to subtype 1 epitomizing the cachectic condition. Clinically, this group was marked by severe weight loss, diminished muscle mass, selective atrophy of fast-twitch muscle fibers—specifically type IIA and type IIX—and consequentially, worse survival outcomes compared to subtype 2. This bipartite molecular classification provides a meaningful framework by which to understand the spectrum of muscle wasting in cancer beyond classical clinical observations.

Delving into the molecular differences driving these subtypes, the study identified distinct biological pathways that likely orchestrate the muscle catabolism observed in cachexia. Notably, disruptions in posttranscriptional regulation emerged as a critical axis, implicating the complex regulatory interplay between non-coding RNAs—such as microRNAs and long non-coding RNAs (lncRNAs)—and messenger RNAs (mRNAs). Such findings underscore that muscle wasting in cancer is not solely a consequence of gene expression changes but also involves nuanced control at the RNA level, suggesting sophisticated layers of regulatory dysfunction.

Another key aspect of the cachexia-associated molecular profile was the perturbation of neuronal systems within skeletal muscle. This neuronal involvement hints at compromised neuromuscular junction integrity or altered muscle innervation, aligning with emerging evidence that neuronal health is vital for maintaining muscle function and mass. Together with altered immune signaling pathways—namely increased cytokine storm and cellular immune responses—these observations suggest an inflammatory and neuroimmune milieu contributing to muscle degradation.

The extracellular matrix (ECM) pathways were similarly disrupted between the two muscle subtypes. As the ECM provides the structural scaffold for muscle fibers and is instrumental in cell signaling, its dysregulation could exacerbate muscle weakness and architectural remodeling in cachexia. These ECM alterations may reflect fibrosis or other pathological changes compromising muscle tissue integrity, further impairing function.

Metabolic aberrations stood out as a hallmark of the cachexia subtype. A spectrum of metabolic pathways, including xenobiotic metabolism, haemostasis, signal transduction, and amino acid metabolism, displayed significant dysregulation. Particularly fascinating was the involvement of pathways linked to embryonic and pluripotent stem cell states, suggesting a reversion or disruption of muscle cellular identity and regeneration capacity. This metabolic rewiring likely contributes to muscle atrophy and impaired recovery, highlighting potential metabolic vulnerabilities amenable to future intervention.

The discovery of these intertwined, higher-order gene regulatory networks paints a complex picture of cancer cachexia, emphasizing that muscle wasting emerges from the convergence of multiple molecular signals rather than isolated perturbations. Within this regulatory web, certain lncRNAs and microRNAs appear to act as hubs—critical nodes that integrate various signaling streams. These hub non-coding RNAs represent compelling targets for mechanistic studies and therapeutic exploration, as modulating their activity could recalibrate the pathological gene expression landscape driving cachexia.

Importantly, the study demonstrates the power of combining advanced sequencing technology with robust computational frameworks like iNMF to deconvolute heterogenous clinical samples. By moving beyond traditional linear analyses and embracing integrative, network-based approaches, researchers can now identify biologically meaningful muscle subtypes that correlate with clinical outcomes. This stratification lays the groundwork for personalized therapeutic strategies tailored to the molecular phenotype of cachexia in individual patients.

The clinical ramifications of distinguishing molecular subtypes within cancer-associated muscle wasting are profound. Current cachexia management remains largely supportive, lacking targeted treatments. The elucidation of specific pathways and gene networks offers a roadmap for the development of novel interventions—whether they be small molecules, RNA-based therapeutics, or biologics—that can mitigate or reverse muscle loss. Furthermore, molecular subtype classification might inform prognostic assessments and guide clinical decision-making in oncology.

This pioneering research also invites broader questions about the crosstalk between tumor biology and systemic tissue remodeling. How tumor-derived factors orchestrate these complex muscle responses, and whether similar molecular subtypes exist across other cancer types or comorbid conditions involving muscle wasting, remain to be explored. Such insights could ultimately reshape our understanding of cancer as a multi-organ disease with far-reaching systemic effects.

In conclusion, the identification of discrete molecular subtypes in the skeletal muscle of cancer patients marks a significant milestone in the quest to demystify cancer cachexia. By illuminating the underlying regulatory networks and biological processes involved in muscle wasting, this study propels the field toward mechanistic clarity and therapeutic innovation. As the landscape of cancer treatment evolves, integrating molecular subtyping of cachexia may enhance patient care and improve survival outcomes—offering renewed hope for those afflicted by this debilitating syndrome.

Subject of Research: Molecular subtypes of human skeletal muscle in cancer cachexia.

Article Title: Molecular subtypes of human skeletal muscle in cancer cachexia.

Article References:
Bhatt, B.J., Ghosh, S., Mazurak, V. et al. Molecular subtypes of human skeletal muscle in cancer cachexia. Nature (2025). https://doi.org/10.1038/s41586-025-09502-0

Image Credits: AI Generated

Cardiac cachexia represents a severe decline in heart muscle mass and function, observed in patients with advanced cancer, notably those afflicted by lung adenocarcinoma. Unlike conventional manifestations of heart disease, cardiac cachexia involves a multifaceted cascade of molecular alterations orchestrated by tumor-host interactions. The research team employed state-of-the-art transcriptomic and proteomic profiling techniques to map these alterations in affected cardiac tissue, revealing a distinct signature linked to tumor-derived factors.

At the molecular level, lung adenocarcinoma appears to trigger a systemic inflammatory response that profoundly impacts myocardial metabolism and structural integrity. Key mediators such as pro-inflammatory cytokines and tumor-derived exosomes were identified as pivotal agents inciting myocardial atrophy. These bioactive molecules disrupt calcium homeostasis, mitochondrial function, and redox balance within cardiomyocytes, ultimately compromising cardiac output and fostering progressive heart failure.

Intriguingly, the study revealed an unexpected upregulation of specific microRNAs (miRNAs) in the myocardium of cancer-bearing subjects. These miRNAs modulate gene expression networks responsible for muscle protein synthesis and degradation, effectively tipping the balance towards proteolysis and cellular apoptosis. The elucidation of these miRNA profiles not only enhances our understanding of cardiac cachexia but also presents potential biomarkers for early detection and personalized interventions.

In addition to these transcriptomic insights, proteomic analyses uncovered alterations in energy metabolism pathways within the failing heart. Enzymes critical for fatty acid oxidation and oxidative phosphorylation were markedly downregulated, hinting at a metabolic reprogramming that favors catabolism over energy production. This metabolic shift parallels observations in skeletal muscle wasting associated with cachexia, reinforcing the systemic nature of cancer-induced catabolic states.

The interplay between lung adenocarcinoma-derived factors and cardiac tissue extends beyond mere inflammatory signaling. The researchers highlighted aberrant activation of ubiquitin-proteasome and autophagy-lysosome pathways in cardiac cells, mechanisms traditionally associated with protein quality control. The excessive activation of these catabolic pathways instigates accelerated degradation of structural proteins, exacerbating myocardial wasting.

Furthermore, mitochondrial dysfunction emerged as a central feature of cardiac cachexia in this context. The team documented impaired mitochondrial biogenesis and increased production of reactive oxygen species (ROS) within cardiomyocytes. This oxidative stress not only damages mitochondrial DNA but also amplifies apoptotic signaling cascades, cumulatively undermining cardiac cellular viability.

These molecular revelations carry profound clinical implications. Current management of cancer patients rarely addresses cardiac cachexia explicitly, leading to overlooked deterioration of cardiac health that significantly influences morbidity and mortality. With the identification of specific molecular signatures, there is now potential to develop targeted therapeutics aimed at mitigating heart muscle loss without impeding oncologic treatment efficacy.

Translational strategies emerging from this research may involve pharmacologic modulation of miRNA activity, cytokine blockade, and mitochondrial protection to preserve cardiac function in lung adenocarcinoma patients. Additionally, advanced imaging coupled with molecular biomarkers could facilitate earlier diagnosis of cardiac cachexia, enabling timely intervention before clinical heart failure ensues.

This research also underscores the necessity of integrative cardio-oncology care models that monitor cardiac function as an integral component of cancer management. Interdisciplinary collaboration between oncologists and cardiologists will be vital for implementing these molecular insights into clinical practice, improving patient outcomes through comprehensive surveillance and tailored treatment paradigms.

Another critical facet illuminated by the study involves the role of tumor microenvironment-derived exosomes. These extracellular vesicles serve as vehicles for transferring oncogenic signals to distant organs, including the heart. By unravelling the cargo profiles of these exosomes, the research paves the way for novel liquid biopsy approaches to detect early signs of cardiac involvement in lung cancer.

Moreover, the study’s findings prompt reevaluation of adjuvant therapies currently employed in oncology, some of which may exacerbate cardiac cachexia. A delicate balance must be struck between preserving antitumor efficacy and preventing collateral cardiac damage, highlighting the importance of molecularly guided treatment regimens.

The recognition of lung adenocarcinoma as a systemic disease impacting cardiac muscle challenges the traditional compartmentalization of oncology and cardiology. It calls for expanded research focusing on the crosstalk mechanisms at the molecular level that precipitate multi-organ involvement in cancer. Such insights hold promise for revolutionizing both cancer care and cardiology by bridging gaps between disciplines.

Looking forward, larger cohort studies and clinical trials will be imperative to validate these molecular signatures and translate them into standardized diagnostic panels and therapeutic targets. The integration of multi-omics data sets encompassing genomics, proteomics, and metabolomics will enhance the resolution of cardiac cachexia’s molecular landscape, fostering precision medicine in cardio-oncology.

In conclusion, the pioneering work by Fu and colleagues marks a significant leap in understanding how lung adenocarcinoma orchestrates cardiac cachexia through intricate molecular signatures. It highlights an urgent need to address cardiac complications in the cancer continuum, emphasizing molecular diagnostics and targeted therapeutics as pathways to improved survival and quality of life for patients facing the dual burden of cancer and heart disease. This comprehensive molecular portrait opens new horizons for cardio-oncology, inviting innovation and collaboration to combat this devastating syndrome.

Subject of Research: Molecular mechanisms of lung adenocarcinoma-driven cardiac cachexia in the field of cardio-oncology

Article Title: Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia

Article References:
Fu, Z., Lin, Z., Chen, S. et al. Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia. Med Oncol 42, 406 (2025). https://doi.org/10.1007/s12032-025-02933-9

Image Credits: AI Generated